Distribution and clinical significance of EGFR mutations in phase Ⅰ non-small-cell lung cancer / 中华胸心血管外科杂志
Chinese Journal of Thoracic and Cardiovascular Surgery
;
(12): 547-549, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-672017
ABSTRACT
Objective To investigate the distribution and clinical significance of EGFR mutations in phase Ⅰ non-smallcell lung cancer(NSCLC).Methods We examined 272 consecutive phase Ⅰ NSCLC patients' tumor samples for EGFR mutations in exons 18,19,20 and 21 using the Amplification Refractory Mutation System(ARMS).Results 154 patients (56.62%)were identified with mutations in the series of 272.Of all the mutations identified,2 (1.3%) were aminoacidic substitutions (G719 S) in exon 18,53 (34.4 %) were in frame deletions (19-del) in exon 19,6 (3.9 %) were insertional mutations (20-ins) in exon 19 and 97 (63.9 %) were aminoacidic substitutions (L858 R) in exon 21.There were 11 patients with coexisting mutations in other exons.The probability of the coexisting resistance mutations (20-ins) in exon 21 was significantly higher than that in exon 19 (P < 0.05).Mutations in adenocarcinoma samples (148/223,66.4%) were more frequent than that in squamous carcinoma(2/40,5%),while mutations in adeno-squamous carcinoma were highest in all histologic types (P < 0.05).Conclusion EGFR mutations in phase Ⅰ NSCLC in Shanghai and surrounding areas were 56.62%.Mutations were more frequent in particular histologic types,e.g.adenocarcinoma and adeno-squamous carcinoma.Exon 19 deletion mutations and the substitution mutation L858R in exon 21 are the most frequent in NSCLC.And the probability of coexisting 20-ins mutations in exon 21 was significantly higher than which in exon 19.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Chinese Journal of Thoracic and Cardiovascular Surgery
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS